Imaging of her2/neu expression in bt-474 human breast cancer xenografts in athymic mice using [99mtc]-hynic-trastuzumab (herceptin) fab fragments

Nuclear Medicine Communications

Volumn 26, Issue 5, 2005, Pages 427-432

  Tang, Ying ^a   Scollard, Deborah ^b   Chen, Paul ^c   Wang, Judy ^d   Holloway, Claire ^d   Reilly, Raymond M ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Fab fragments; HER2 neu; HYNIC; Technetium 99m; Trastuzumab (Herceptin)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; N HYDROXYSUCCINIMIDE ESTER; SUCCINIC ACID DERIVATIVE; TECHNETIUM 99M; TRASTUZUMAB; TRASTUZUMAB TC 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BLOOD; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; GENE OVEREXPRESSION; IMAGING SYSTEM; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT; ULTRAFILTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; KINETICS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TECHNETIUM; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 18144416577     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200505000-00006     Document Type: Article

References (27)

1. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312:513-516.
2. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18:3651-3664.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
4. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28:13-19.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
6. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
7. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61(suppl 2):37-42.
8. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
9. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96:739-749.
10. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96:759-769.
11. Leonard DS, Hill AD, Kelly L, Dijkstra B, McDermott E, O'Higgins NJ. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 2002; 89:262-271.
12. van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001; 37(suppl 1):11-17.
13. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20:3095-3105.
14. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med 2001; 345:995-996.
15. 111In labeled Herceptin. Nucl Med Biol 2002; 29:599-606.
16. Kobayashi H, Shirakawa K, Kawamoto S, Saga T, Sato N, Hiraga A, et al. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). Cancer Res 2002; 62:860-866.
17. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22:701-706.
18. Palm S, Enmon RM Jr, Matei C, Kolbert KS, Xu S, Zanzonico PB, et al. Pharmacokinetics and biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 2003; 44:1148-1155.
19. 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005; 32:51-58.
20. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992; 148:1149-1154.
21. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990; 31:2022-2028.
22. King TP, Zhao SW, Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry 1986; 25:5774-5779.
23. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (NY) 1992; 10:163-167.
24. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89:4285-4289.
25. Harwerth IM, Wels W, Marte BM, Hynes NE. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 1992; 267:15-160-15-167.
26. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-760.
27. Kelley RF, O'Connell MP. Thermodynamic analysis of an antibody functional epitope. Biochemistry 1993; 32:6828-6835.